Economist says NICE should approve fewer costly drugs.
作者信息
O'Dowd Adrian
出版信息
BMJ. 2007 Jul 7;335(7609):11. doi: 10.1136/bmj.39265.337813.DB.
Abstract
摘要
相似文献
1
Economist says NICE should approve fewer costly drugs.
BMJ. 2007 Jul 7;335(7609):11. doi: 10.1136/bmj.39265.337813.DB.
2
NICE and the challenge of cancer drugs.
BMJ. 2009 Jan 13;338:b67. doi: 10.1136/bmj.b67.
3
NICE is too generous in approving drugs, analysis says.
BMJ. 2015 Feb 19;350:h955. doi: 10.1136/bmj.h955.
4
Successful procurement. A licence to spend money?
Health Serv J. 1997 Jun 19;107(5558):suppl 1-5.
5
NICE appraisals should be everybody's business.
BMJ. 2007 May 5;334(7600):936-8. doi: 10.1136/bmj.39190.420081.94.
6
Speeding up access to new drugs threatens evidence based medicine, says health economist.
BMJ. 2016 Jan 15;352:i263. doi: 10.1136/bmj.i263.
7
Health Technology Assessment. NICE goes global.
BMJ. 2009 Jan 28;338:b103. doi: 10.1136/bmj.b103.
8
Comparative effectiveness research: NICE for the NHS, but false starts for the US.
Clin Ther. 2008 Sep;30(9):1702-3. doi: 10.1016/j.clinthera.2008.09.007.
9
NICE or nasty? National Institute of Clinical Excellence.
Clin Oncol (R Coll Radiol). 2002 Apr;14(2):86-8. doi: 10.1053/clon.2002.0069.
10
NICE: friend and foe.
Nat Clin Pract Oncol. 2007 Mar;4(3):135. doi: 10.1038/ncponc0746.
Zotero 插件